Description: AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Home Page: www.allovir.com
ALVR Technical Analysis
1100 Winter Street
Waltham,
MA
02451
United States
Phone:
617 433 2605
Officers
| Name | Title |
|---|---|
| Mr. David L. Hallal | Exec. Chairman |
| Dr. Diana M. Brainard M.D. | CEO & Director |
| Mr. Vikas Sinha C.A., CPA, M.B.A. | Pres, CFO & Director |
| Dr. Jeroen van Beek Ph.D. | Consultant |
| Mr. Agustin Melian M.D. | Advisor |
| Mr. Brett R. Hagen | Chief Accounting Officer |
| Mr. Dana M. Alexander M.B.A. | Sr. VP of Technical Operations |
| Dr. Ann M. Leen Ph.D. | Chief Scientific Officer |
| Ms. Sonia Choi | Sr. VP of Corp. Affairs & Investor Relations |
| Mr. Edward Miller J.D. | Gen. Counsel & Sec. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.465 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-07-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 107 |